Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)

Blood

Volumn 107, Issue 10, 2006, Pages 4122-4129

  Secchiero, Paola ^a   Barbarotto, Elisa ^b   Tiribelli, Mario ^b   Zerbinati, Carlotta ^b   Di Iasio, Maria Grazia ^b   Gonelli, Arianna ^b   Cavazzini, Francesco ^b   Campioni, Diana ^b   Fanin, Renato ^b   Cuneo, Antonio ^b   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD19 ANTIGEN; CHLORAMBUCIL; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DEATH RECEPTOR 5; FLUDARABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MESSENGER RNA; NUTLIN 3; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE ACTIVATION; GENOTOXICITY; HUMAN; IN VITRO STUDY; LYMPHATIC LEUKEMIA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 33646574651     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4465     Document Type: Article

References (40)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
2. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49-58.
3. Gostissa M, Hofmann TG, Will H, Del Sal G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol. 2003;15:351-357.
4. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23:1547-1556.
5. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
6. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65:1918-1924.
7. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low grade B-cell malignancies using biological response modifiers. Semin Oncol. 2002;29:10-24.
8. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000;343:1799-1801.
9. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
10. Cuneo A, Bigoni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders: clinicobiological significance. Haematologica. 2002;87:44-51.
11. + cells). J Gen Virol. 1992;73:417-421.
12. SuperArray Bioscience Corporation. Gene list. OHS-802; http://www.superarray.com/gene_array_product/HTML/OHS-802.html. Accessed May 2, 2004.
13. SuperArray Bioscience Corporation. Gene list. HS-603; http://www.superarray.com/gene_array_product/HTML/HS-603.html. Accessed May 2, 2004.
14. Chou T, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
15. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
16. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
17. Rossi D, Capello D, Gloghini A, et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004;89:154-164.
18. Valganon M, Giraldo P, Agirre X, et al. p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol. 2005;129:53-59.
19. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617-2623.
20. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
21. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
22. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
23. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
24. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 2004;104:1428-1434.
25. Pettitt AR, Clarke AR, Cawley JC, Griffiths SD. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol. 1999;105:986-988.
26. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
27. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
28. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
29. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150-3159.
30. Stühmer T, Chatterjee M, Hildebrandt M, et al. Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609-3617.
31. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem. 1998;273:33048-33053.
32. Dumaz N, Meek DW. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 1999;18:7002-7010.
33. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999;19:1751-1758.
34. Wu Z, Earle J, Saito S, Anderson CW, Appella E, Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol. 2002;22:2441-2449.
35. Chao C, Hergenhahn M, Kaeser MD, et al. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 response. J Biol Chem. 2003;278:41028-41033.
36. Thompson T, Tovar C, Yang H. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem. 2004;279:53015-53022.
37. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100:3741-3748.
38. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345-357.
39. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577-590.
40. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005; 280:19166-19176.